The aim of our study was to test whether EDHB, a small-molecule prolyl hydroxylase inhibitor (PHI) which inhibits the degradation of HIF-1α, prevents the steroid-associated osteonecrosis of the femoral head. This evidence concerns the gene HIF1A and osteonecrosis.